Abstract
Current coronavirus disease (COVID-19) is regarded as a primary respiratory and vascular disease leading to acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and endothelial dysfunction (ED) in severe cases. The causative virus of COVID-19 is SARS-CoV-2, which binds angiotensin-converting enzyme 2 (ACE2) for its entry. It has been shown that ED is linked to various COVID-19 complications since endothelial cells are regarded as the chief barrier against SARS-CoV- 2 invasion. SARS-CoV-2-indued ED leads to endotheliitis and thrombosis due to endothelial nitric oxide (NO) inhibition with subsequent vasoconstriction and tissue hypoxia. Loss of vasodilator NO and anti-thrombin factor from endothelial SARS-CoV-2 infection contribute to the progression of vascular dysfunction and coagulopathy. Therefore, NO restoration improves pulmonary function and hinders viral replication during respiratory viral infections, including COVID-19. L-arginine is a semiessential amino acid that has antiviral and immunomodulatory effects as well as improves the biosynthesis of NO in endothelial cells. L-arginine may reduce the risk of ALI through inhibition of generation of peroxynitrite and suppression of the release of proinflammatory cytokines from alveolar macrophages. Of interest, restoration of NO by L-arginine may attenuate SARS-CoV-2 infection through different mechanisms, including reduction binding of SARS-CoV-2 to ACE2, inhibition of transmembrane protease serine-type 2 (TMPRSS2), critical for the activation of SARS-CoV-2 spike protein and cellular entry, inhibition proliferation and replication of SARS-CoV-2, and prevention of SARS-CoV-2-induced coagulopathy. In conclusion, through antiviral and immunomodulatory effects, L-arginine and released NO have mutual and interrelated actions against SARS-CoV-2 infection.
Keywords: SARS-CoV-2, COVID-19, L-arginine, antiviral effects, immunomodulatory effects, endothelial nitric oxide.
Graphical Abstract
[http://dx.doi.org/10.1016/j.bcp.2021.114431] [PMID: 33515531]
[http://dx.doi.org/10.3389/fnut.2021.649128] [PMID: 33816542]
[http://dx.doi.org/10.3389/fmed.2021.644295] [PMID: 33718411]
[http://dx.doi.org/10.1038/s41577-021-00536-9] [PMID: 33824483]
[http://dx.doi.org/10.1016/j.jaci.2020.08.031] [PMID: 32920092]
[http://dx.doi.org/10.1111/aas.13757] [PMID: 33296498]
[http://dx.doi.org/10.1039/D0NR07484E] [PMID: 33403376]
[http://dx.doi.org/10.1152/ajpheart.00631.2020] [PMID: 32857616]
[http://dx.doi.org/10.1016/j.niox.2018.12.003] [PMID: 30528912]
[http://dx.doi.org/10.1016/j.niox.2020.07.003] [PMID: 32681986]
[http://dx.doi.org/10.1016/j.micpath.2020.104303] [PMID: 32504845]
[http://dx.doi.org/10.1016/j.arr.2020.101201] [PMID: 33157320]
[http://dx.doi.org/10.1016/j.advms.2018.08.018] [PMID: 30605863]
[http://dx.doi.org/10.1161/JAHA.117.006224] [PMID: 29151027]
[http://dx.doi.org/10.1038/s41577-020-0335-0] [PMID: 32355328]
[http://dx.doi.org/10.1021/acs.jafc.8b00726] [PMID: 29595256]
[http://dx.doi.org/10.1097/shk.0b013e31804a59bd] [PMID: 17558346]
[http://dx.doi.org/10.1016/j.clnu.2004.11.011] [PMID: 15896421]
[http://dx.doi.org/10.1039/D0NJ03823G]
[http://dx.doi.org/10.1016/j.micinf.2020.05.006] [PMID: 32425647]
[http://dx.doi.org/10.1371/journal.pone.0191030] [PMID: 29370244]
[http://dx.doi.org/10.1016/j.niox.2018.03.009] [PMID: 29549005]
[http://dx.doi.org/10.1038/s41390-020-1053-9] [PMID: 32634818]
[http://dx.doi.org/10.1164/rccm.202005-1906ED] [PMID: 32437250]
[http://dx.doi.org/10.1016/j.anpede.2022.01.001] [PMID: 35131220]
[http://dx.doi.org/10.1016/j.eclinm.2021.101125] [PMID: 34522871]